lilly glp 1 trulicity Launches in the US – First Ever Ready-to-Use Once-Weekly -1 Receptor Agonist The FDA approved a new

FDA's preliminary evaluation has not found evidence that use of these medicines causes suicidal thoughts or actions

Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine

While occasional small floaters are common and usually harmless, a sudden shower of new floaters needs prompt evaluation

Important considerations for both medications BMI and Co-morbidities : Both are typically prescribed for individuals with a BMI 30, or 27 with weight-related conditions

That distinction affects safety review, labeling requirements, dosing instruction standards, and buyer due diligence obligations